piperacillin ๐Ÿถ Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, 6-aminopenicillanic acid derivatives 2187 61477-96-1

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • piperacillin hydrate
  • piperacillin
  • piperacillin sodium
  • pipracil
  • piperacillin sodium salt
Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.
  • Molecular weight: 517.56
  • Formula: C23H27N5O7S
  • CLOGP: 1.36
  • LIPINSKI: 2
  • HAC: 12
  • HDO: 3
  • TPSA: 156.43
  • ALOGS: -3.64
  • ROTB: 6

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
14 g P
14 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 714.30 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 71 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 772.85 ยตM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.27 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 4 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.50 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 0.96 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Dec. 29, 1981 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 98.41 18.13 115 8539 127558 50468912
Pyrexia 95.41 18.13 204 8450 379999 50216471
Sepsis 81.90 18.13 107 8547 132818 50463652
Toxic epidermal necrolysis 77.59 18.13 47 8607 20945 50575525
Acute kidney injury 72.17 18.13 135 8519 227923 50368547
Rash maculo-papular 62.71 18.13 45 8609 26596 50569874
Septic shock 62.45 18.13 62 8592 57113 50539357
Respiratory failure 60.18 18.13 76 8578 91105 50505365
Multiple organ dysfunction syndrome 59.49 18.13 57 8597 50280 50546190
Pancytopenia 58.59 18.13 72 8582 83958 50512512
Eosinophilia 49.70 18.13 34 8620 18618 50577852
Tubulointerstitial nephritis 48.47 18.13 31 8623 15180 50581290
Renal failure 48.07 18.13 74 8580 106559 50489911
Disseminated intravascular coagulation 47.48 18.13 32 8622 17103 50579367
Fatigue 46.91 18.13 32 8622 707569 49888901
Dermatitis exfoliative generalised 45.85 18.13 18 8636 3108 50593362
Platelet count decreased 45.54 18.13 70 8584 100656 50495814
Tonic clonic movements 40.76 18.13 13 8641 1224 50595246
Urinary tract obstruction 40.16 18.13 14 8640 1734 50594736
Drug reaction with eosinophilia and systemic symptoms 39.01 18.13 35 8619 28389 50568081
Leukopenia 37.89 18.13 52 8602 67476 50528994
Arthralgia 37.74 18.13 14 8640 438688 50157782
Pseudomembranous colitis 37.24 18.13 15 8639 2770 50593700
Rash morbilliform 33.53 18.13 14 8640 2832 50593638
Haemolytic anaemia 32.26 18.13 20 8634 9272 50587198
Heparin-induced thrombocytopenia 32.14 18.13 15 8639 3950 50592520
Biloma 31.58 18.13 6 8648 61 50596409
Headache 30.78 18.13 25 8629 506510 50089960
Acute generalised exanthematous pustulosis 30.43 18.13 19 8635 8919 50587551
Haemoglobin decreased 30.24 18.13 67 8587 127149 50469321
Drug ineffective 28.75 18.13 61 8593 819272 49777198
Agranulocytosis 28.65 18.13 26 8628 21395 50575075
Joint swelling 28.63 18.13 4 8650 245282 50351188
Febrile neutropenia 28.54 18.13 56 8598 97611 50498859
Nephropathy toxic 27.16 18.13 17 8637 8012 50588458
Drug intolerance 26.96 18.13 3 8651 219101 50377369
Alopecia 26.36 18.13 5 8649 245042 50351428
Hepatic function abnormal 26.04 18.13 30 8624 32651 50563819
Pleural effusion 25.38 18.13 48 8606 81406 50515064
Blood creatinine increased 25.13 18.13 46 8608 76114 50520356
Peripheral swelling 24.89 18.13 3 8651 205933 50390537
Linear IgA disease 24.85 18.13 9 8645 1245 50595225
Aspergillus infection 24.49 18.13 15 8639 6806 50589664
Hypokalaemia 23.96 18.13 49 8605 87943 50508527
Leukocytosis 23.73 18.13 24 8630 22555 50573915
Neutropenia 23.65 18.13 67 8587 147898 50448572
Autoimmune haemolytic anaemia 23.07 18.13 12 8642 3987 50592483
Dizziness 22.40 18.13 16 8638 346353 50250117
Abdominal discomfort 22.35 18.13 6 8648 231635 50364835
Transplant rejection 22.07 18.13 16 8638 9593 50586877
Anaemia 21.69 18.13 93 8561 252363 50344107
Unresponsive to stimuli 20.93 18.13 26 8628 30583 50565887
Fall 19.72 18.13 17 8637 334915 50261555
Product contamination microbial 19.72 18.13 5 8649 205 50596265
Hypotension 19.65 18.13 86 8568 235383 50361087
Stevens-Johnson syndrome 19.09 18.13 21 8633 21731 50574739
Prothrombin time prolonged 18.69 18.13 14 8640 8824 50587646
Adrenocorticotropic hormone deficiency 18.51 18.13 5 8649 263 50596207
Pain in extremity 18.44 18.13 12 8642 272853 50323617
Intravascular haemolysis 18.24 18.13 5 8649 278 50596192
Platelet count increased 18.18 18.13 17 8637 14523 50581947

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Tubulointerstitial nephritis 106.88 16.44 73 11391 17570 29545493
Acute kidney injury 94.72 16.44 270 11194 264997 29298066
Thrombocytopenia 89.42 16.44 175 11289 134648 29428415
Sepsis 80.20 16.44 173 11291 142509 29420554
Drug reaction with eosinophilia and systemic symptoms 67.79 16.44 68 11396 27924 29535139
Pyrexia 66.70 16.44 253 11211 287369 29275694
Multiple organ dysfunction syndrome 51.88 16.44 90 11374 63026 29500037
Eosinophilia 48.51 16.44 51 11413 22110 29540953
Rash maculo-papular 46.36 16.44 52 11412 24237 29538826
Disseminated intravascular coagulation 45.56 16.44 47 11417 19933 29543130
Clostridial infection 44.66 16.44 23 11441 3292 29559771
Agranulocytosis 43.08 16.44 46 11418 20294 29542769
Cholestasis 41.01 16.44 48 11416 23414 29539649
Renal tubular necrosis 40.71 16.44 38 11426 14277 29548786
Neutropenia 40.04 16.44 127 11337 131584 29431479
Rash 38.20 16.44 160 11304 189659 29373404
Septic shock 37.50 16.44 78 11386 62482 29500581
Dizziness 34.83 16.44 15 11449 189669 29373394
Renal failure 34.80 16.44 113 11351 118486 29444577
Stevens-Johnson syndrome 34.39 16.44 37 11427 16460 29546603
Respiratory failure 31.66 16.44 96 11368 97035 29466028
Nephropathy toxic 29.52 16.44 28 11436 10728 29552335
Congenital pneumonia 29.28 16.44 7 11457 95 29562968
Fatigue 29.03 16.44 49 11415 316772 29246291
Heparin-induced thrombocytopenia 28.71 16.44 20 11444 4959 29558104
Gamma-glutamyltransferase increased 28.59 16.44 43 11421 26694 29536369
Toxic epidermal necrolysis 28.22 16.44 35 11429 18118 29544945
Clostridium difficile colitis 28.18 16.44 30 11434 13182 29549881
Blood alkaline phosphatase increased 28.01 16.44 44 11420 28362 29534701
Blood creatinine increased 26.68 16.44 83 11381 85019 29478044
Choroiditis 26.32 16.44 11 11453 977 29562086
Death 26.06 16.44 59 11405 342025 29221038
Pancytopenia 25.97 16.44 81 11383 83087 29479976
Febrile neutropenia 25.22 16.44 98 11366 112142 29450921
Alanine aminotransferase increased 24.89 16.44 72 11392 70872 29492191
Blood bilirubin increased 24.83 16.44 46 11418 33847 29529216
Aspartate aminotransferase increased 24.30 16.44 64 11400 59661 29503402
Nephritis 23.63 16.44 13 11451 2123 29560940
Autoimmune haemolytic anaemia 23.47 16.44 16 11448 3832 29559231
Transplant rejection 23.43 16.44 23 11441 9189 29553874
Pneumonia staphylococcal 22.96 16.44 14 11450 2771 29560292
Subclavian artery occlusion 22.78 16.44 6 11458 123 29562940
Skin exfoliation 22.22 16.44 35 11429 22610 29540453
Hepatic failure 22.12 16.44 42 11422 31470 29531593
Acute respiratory distress syndrome 21.88 16.44 35 11429 22900 29540163
Chondritis 21.88 16.44 6 11458 144 29562919
Arthralgia 21.26 16.44 14 11450 139603 29423460
Haemodialysis 20.17 16.44 22 11442 9932 29553131
Dialysis 19.71 16.44 22 11442 10186 29552877
Interstitial lung disease 19.68 16.44 58 11406 57660 29505403
Anaphylactic reaction 19.66 16.44 37 11427 27536 29535527
Rash erythematous 19.34 16.44 32 11432 21530 29541533
Organ failure 19.29 16.44 11 11453 1925 29561138
Platelet count decreased 18.52 16.44 85 11379 104587 29458476
Weight decreased 18.20 16.44 19 11445 150886 29412177
Drug eruption 18.00 16.44 27 11437 16714 29546349
Hepatic function abnormal 17.97 16.44 44 11420 39215 29523848
Device related infection 17.94 16.44 26 11438 15610 29547453
Weight increased 17.73 16.44 4 11460 76663 29486400
Headache 17.72 16.44 25 11439 173982 29389081
Petechiae 17.46 16.44 19 11445 8552 29554511
Leukopenia 17.43 16.44 54 11410 55149 29507914
Renal impairment 17.43 16.44 70 11394 81263 29481800
Blister 17.13 16.44 29 11435 19877 29543186

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 153.11 15.79 351 16458 448889 64033034
Tubulointerstitial nephritis 142.78 15.79 93 16716 30816 64451107
Thrombocytopenia 142.02 15.79 228 16581 223573 64258350
Pyrexia 128.90 15.79 377 16432 558267 63923656
Sepsis 121.34 15.79 216 16593 230125 64251798
Drug reaction with eosinophilia and systemic symptoms 102.27 15.79 96 16713 54121 64427802
Rash maculo-papular 93.98 15.79 86 16723 46940 64434983
Septic shock 90.61 15.79 124 16685 105313 64376610
Toxic epidermal necrolysis 84.25 15.79 73 16736 37093 64444830
Eosinophilia 82.72 15.79 73 16736 38003 64443920
Multiple organ dysfunction syndrome 80.77 15.79 115 16694 101298 64380625
Renal failure 74.13 15.79 153 16656 181535 64300388
Fatigue 71.07 15.79 55 16754 748675 63733248
Pancytopenia 62.37 15.79 124 16685 143185 64338738
Arthralgia 58.77 15.79 21 16788 442239 64039684
Clostridial infection 58.59 15.79 28 16781 5091 64476832
Agranulocytosis 57.77 15.79 60 16749 38169 64443754
Disseminated intravascular coagulation 56.65 15.79 55 16754 32293 64449630
Respiratory failure 54.62 15.79 126 16683 161057 64320866
Heparin-induced thrombocytopenia 53.11 15.79 31 16778 8448 64473475
Dizziness 52.91 15.79 23 16786 430140 64051783
Nephropathy toxic 51.43 15.79 40 16769 17474 64464449
Platelet count decreased 50.26 15.79 125 16684 167586 64314337
Autoimmune haemolytic anaemia 50.03 15.79 28 16781 7048 64474875
Transplant rejection 49.49 15.79 39 16770 17362 64464561
Renal tubular necrosis 47.23 15.79 42 16767 22068 64459855
Neutropenia 46.80 15.79 153 16656 239471 64242452
Headache 46.30 15.79 42 16767 529425 63952498
Acute generalised exanthematous pustulosis 43.23 15.79 33 16776 14025 64467898
Peripheral swelling 42.89 15.79 3 16806 209150 64272773
Stevens-Johnson syndrome 41.72 15.79 48 16761 34201 64447722
Joint swelling 41.65 15.79 4 16805 215378 64266545
Pseudomembranous colitis 39.03 15.79 21 16788 4895 64477028
Fall 38.94 15.79 31 16778 416795 64065128
Cholestasis 38.84 15.79 53 16756 44819 64437104
Leukopenia 38.60 15.79 83 16726 101159 64380764
Clostridium difficile colitis 38.05 15.79 41 16768 27182 64454741
Rash 37.85 15.79 226 16583 458323 64023600
Febrile neutropenia 37.68 15.79 121 16688 187536 64294387
Weight increased 36.32 15.79 6 16803 213342 64268581
Drug intolerance 35.03 15.79 4 16805 187988 64293935
Nasopharyngitis 34.54 15.79 5 16804 196068 64285855
Urinary tract obstruction 34.26 15.79 18 16791 3999 64477924
Dialysis 33.89 15.79 31 16778 16889 64465034
Alopecia 32.23 15.79 3 16806 165687 64316236
Blood creatinine increased 30.43 15.79 91 16718 135691 64346232
Dermatitis exfoliative generalised 30.27 15.79 19 16790 5897 64476026
Nephritis 30.14 15.79 16 16793 3630 64478293
Acute respiratory distress syndrome 29.27 15.79 43 16766 38892 64443031
Staphylococcal sepsis 28.54 15.79 25 16784 12874 64469049
Hypotension 27.78 15.79 182 16627 380792 64101131
Petechiae 27.71 15.79 29 16780 18597 64463326
Renal impairment 27.02 15.79 87 16722 134930 64346993
Weight decreased 26.97 15.79 21 16788 285718 64196205
Interstitial lung disease 26.30 15.79 70 16739 97662 64384261
Tonic clonic movements 26.23 15.79 12 16797 1977 64479946
Prothrombin time prolonged 26.13 15.79 26 16783 15715 64466208
Intravascular haemolysis 26.02 15.79 9 16800 711 64481212
Hepatic function abnormal 25.98 15.79 54 16755 64259 64417664
Choroiditis 25.93 15.79 10 16799 1077 64480846
Haemolytic anaemia 25.70 15.79 26 16783 16027 64465896
Pain in extremity 25.31 15.79 25 16784 303060 64178863
Abdominal discomfort 25.31 15.79 8 16801 182314 64299609
Linear IgA disease 25.29 15.79 13 16796 2761 64479162
Haemoglobin decreased 25.08 15.79 109 16700 194954 64286969
Enterococcal infection 25.07 15.79 24 16785 13842 64468081
Blood alkaline phosphatase increased 24.81 15.79 49 16760 56230 64425693
Rash erythematous 24.72 15.79 45 16764 48588 64433335
Aspartate aminotransferase increased 24.71 15.79 78 16731 119710 64362213
Clostridium difficile infection 24.43 15.79 38 16771 36125 64445798
Haemodialysis 24.36 15.79 26 16783 17051 64464872
Hepatic failure 24.14 15.79 48 16761 55346 64426577
Biloma 23.97 15.79 6 16803 151 64481772
Muscle spasms 23.91 15.79 4 16805 141019 64340904
Subclavian artery occlusion 23.67 15.79 6 16803 159 64481764
Drug ineffective 23.60 15.79 126 16683 840121 63641802
Aspergillus infection 23.47 15.79 25 16784 16354 64465569
Antibiotic level above therapeutic 23.47 15.79 8 16801 605 64481318
Skin exfoliation 23.41 15.79 42 16767 44843 64437080
Leukocytosis 23.22 15.79 38 16771 37702 64444221
Blood bilirubin increased 22.87 15.79 48 16761 57505 64424418
Rash morbilliform 22.58 15.79 15 16794 5126 64476797
Antibiotic level below therapeutic 22.48 15.79 5 16804 74 64481849
Staphylococcal infection 22.19 15.79 44 16765 50634 64431289
Systemic candida 22.09 15.79 15 16794 5314 64476609
Drug abuse 21.91 15.79 4 16805 132370 64349553
Alanine aminotransferase increased 21.27 15.79 82 16727 138949 64342974
Hepatic cytolysis 21.12 15.79 22 16787 14027 64467896
Aplasia pure red cell 20.54 15.79 16 16793 6998 64474925
Pleural effusion 20.48 15.79 76 16733 126483 64355440
Neutrophilic dermatosis 20.30 15.79 7 16802 548 64481375
Respiratory distress 20.04 15.79 43 16766 52288 64429635
Encephalopathy 19.91 15.79 46 16763 58773 64423150
White blood cell count increased 19.52 15.79 49 16760 65965 64415958
Pathogen resistance 19.50 15.79 20 16789 12523 64469400
Renal injury 19.42 15.79 22 16787 15407 64466516
Anaphylactic reaction 19.30 15.79 50 16759 68614 64413309
Injection site pain 19.25 15.79 3 16806 111405 64370518
Chondritis 19.23 15.79 5 16804 147 64481776
Depression 19.23 15.79 12 16797 183279 64298644
Toxicity to various agents 18.66 15.79 42 16767 363471 64118452
Extravasation blood 18.59 15.79 6 16803 383 64481540
Toxic skin eruption 18.56 15.79 24 16785 19260 64462663
Acanthosis 18.33 15.79 6 16803 400 64481523
Insomnia 18.08 15.79 15 16794 197821 64284102
Musculoskeletal stiffness 17.83 15.79 5 16804 123201 64358722
Nausea 17.78 15.79 126 16683 785674 63696249
Pneumonia staphylococcal 17.31 15.79 12 16797 4394 64477529
Dermatitis exfoliative 17.00 15.79 17 16792 10335 64471588
Neuralgic amyotrophy 16.97 15.79 5 16804 235 64481688
Organ failure 16.93 15.79 11 16798 3622 64478301
Blood culture positive 16.91 15.79 15 16794 7853 64474070
Skin oedema 16.81 15.79 8 16801 1440 64480483
Chronic hepatitis C 16.63 15.79 6 16803 537 64481386
Pain 16.63 15.79 81 16728 553430 63928493
Gamma-glutamyltransferase increased 16.48 15.79 38 16771 48472 64433451
Bacteraemia 16.42 15.79 27 16782 26884 64455039
Pneumonia pseudomonal 16.16 15.79 12 16797 4891 64477032
Swelling 16.11 15.79 11 16798 160207 64321716
Sinusitis 16.09 15.79 9 16800 145919 64336004
Purpura 15.88 15.79 21 16788 17225 64464698
Contusion 15.81 15.79 5 16804 113960 64367963
Gait disturbance 15.79 15.79 13 16796 172142 64309781

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01CA12 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Penicillins with extended spectrum
ATC J01CR05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
BETA-LACTAM ANTIBACTERIALS, PENICILLINS
Combinations of penicillins, incl. beta-lactamase inhibitors
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Septicemia due to Escherichia coli indication 9323009
Bacterial septicemia indication 10001005 DOID:0040085
Infection due to Pseudomonas aeruginosa indication 11218009
Gonorrhea indication 15628003 DOID:7551
Infection of skin AND/OR subcutaneous tissue indication 19824006
Acute gonococcal cervicitis indication 20943002 DOID:10615
Streptococcal septicemia indication 29577008
Acute gonococcal urethritis indication 29864006
Postoperative infection indication 33910007
Pneumonia due to Pseudomonas indication 41381004
Peritonitis indication 48661000
Lower respiratory tract infection indication 50417007
Pneumonia due to Escherichia coli indication 51530003
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Acute gonococcal endometritis indication 65295003 DOID:7527
Urinary tract infectious disease indication 68566005
Haemophilus influenzae pneumonia indication 70036007
Infection due to Escherichia coli indication 71057007
Bacterial infection due to Serratia indication 71120004
Rhinoscleroma indication 72409005 DOID:11336
Appendicitis indication 74400008 DOID:8337
Abdominal abscess indication 75100008
Septicemia due to Bacteroides indication 79587009
Septicemia due to Serratia indication 82091000
Infection of bone indication 111253001
Female genital tract infection indication 125585007
Infectious disease of abdomen indication 128070006
Infection due to Enterobacteriaceae indication 128945009
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Proteus septicemia indication 300986008
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Septicemia due to enterococcus indication 310669007
Infectious disorder of joint indication 363162000
Infection due to Staphylococcus aureus indication 406602003
Nosocomial pneumonia indication 425464007
Sepsis due to Pseudomonas indication 448813005
Sepsis due to Gram negative bacteria indication 449082003
Urinary tract infection caused by Klebsiella indication 369001000119100
Skin and Skin Structure Bacteroides Fragilis Infection indication
E. Coli Appendicitis indication
Bacteroides Pneumonia indication
Complicated Skin and Skin Structure Staphylococcus Aureus Infection indication
Bacteroides Peritonitis indication
Skin and Skin Structure Enterococcus Infection indication
Prevention of Perioperative Infection indication
Pseudomonas Aeruginosa Urinary Tract Infection indication
Bacteroides Pelvic Inflammatory Disease indication
Bacteroides Pelvic Cellulitis indication
Bacteroides Endometritis indication
E. Coli Peritonitis indication
Pseudomonas Aeruginosa Joint Infection indication
Bacteroides Complicated Appendicitis indication
Enterococcus Urinary Tract Infection indication
E. Coli Pelvic Inflammatory Disease indication
Skin and Skin Structure Serratia Infection indication
Bacteroides Appendicitis indication
Neisseria Gonorrhea Pelvic Cellulitis indication
Enterococcus Peritonitis indication
Cesarean Section Infection Prevention indication
Vaginal Hysterectomy Infection Prevention indication
Enterococcus Pelvic Inflammatory Disease indication
Bacteroides Osteomyelitis indication
Infection Prevention for GI Surgery indication
Enterococcus Joint Infection indication
Clostridium Peritonitis indication
Complicated Skin and Skin Structure Infection indication
Inflammatory Disease of Female Pelvic Organs indication
Pseudomonas Aeruginosa Osteomyelitis indication
Peptostreptococcus Pelvic Inflammatory Disease indication
Complicated Proteus UTI indication
Staphylococcus Nosocomial Pneumonia indication
Skin and Skin Structure Acinetobacter Infection indication
Bacteroides Joint Infection indication
Enterococcus Complicated UTI indication
Skin and Skin Structure Proteus Infection indication
Enterobacter Pneumonia indication
E. Coli Complicated Appendicitis indication
E. Coli Endometritis indication
Diabetic Foot Infection indication
Enterococcus Osteomyelitis indication
Enterococcus Endometritis indication
Complicated UTI with Pseudomonas Aeruginosa indication
Skin and Skin Structure Pseudomonas Aeruginosa Infection indication
Enterococcus Pelvic Cellulitis indication
Ecthyma gangrenosum off-label use 17732003
Sepsis of the newborn off-label use 206376005
Diverticulitis of gastrointestinal tract off-label use 271366000
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis off-label use
Blood coagulation disorder contraindication 64779008 DOID:1247
Kidney disease contraindication 90708001 DOID:557
Infectious mononucleosis contraindication 271558008 DOID:8568
Neutropenic disorder contraindication 303011007 DOID:1227
Pseudomembranous enterocolitis contraindication 397683000




๐Ÿถ Veterinary Drug Use

None

๐Ÿถ Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.79 acidic
pKa2 12.64 acidic

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** ZOSYN WYETH PHARMS N050684 Oct. 22, 1993 DISCN INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 40MG BASE/ML;EQ 5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 4GM BASE/100ML;EQ 500MG BASE/100ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 6900184 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS
EQ 60MG BASE/ML;EQ 7.5MG BASE/ML ZOSYN IN PLASTIC CONTAINER WYETH PHARMS N050750 Feb. 24, 1998 RX INJECTABLE INJECTION 8133883 April 14, 2023 METHOD OF TREATING BACTERIAL INFECTIONS

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL
Penicillin-binding protein 1A Enzyme WOMBAT-PK
Beta-lactamase Enzyme Ki 6.70 CHEMBL
Streptokinase A Enzyme EC50 6.55 WOMBAT-PK

External reference:

IDSource
4019896 VUID
N0000147981 NUI
D00466 KEGG_DRUG
59703-84-3 SECONDARY_CAS_RN
4018917 VANDF
4019896 VANDF
C0031955 UMLSCUI
CHEBI:8232 CHEBI
WPP PDB_CHEM_ID
CHEMBL702 ChEMBL_ID
CHEMBL1200820 ChEMBL_ID
D010878 MESH_DESCRIPTOR_UI
DB00319 DRUGBANK_ID
10921 IUPHAR_LIGAND_ID
X00B0D5O0E UNII
43672 PUBCHEM_CID
203134 RXNORM
1514 MMSL
5304 MMSL
60235 MMSL
d00057 MMSL
002688 NDDF
004832 NDDF
11644000 SNOMEDCT_US
372836004 SNOMEDCT_US
74575000 SNOMEDCT_US
66258-76-2 SECONDARY_CAS_RN

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8860 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8861 INJECTION, SOLUTION 3 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 27 sections
Zosyn in Galaxy Containers HUMAN PRESCRIPTION DRUG LABEL 2 0206-8862 INJECTION, SOLUTION 4 g INTRAVENOUS NDA 27 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-2999 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3374 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3378 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3379 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 25 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3383 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3385 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0409-3390 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3110 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3113 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3114 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3117 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 12 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-3180 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9210 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9213 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 0781-9214 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-012 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-034 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-056 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 26 sections
Piperacillin and Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 22607-679 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 36 g INTRAVENOUS ANDA 26 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-164 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-165 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-166 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 4 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-175 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 2 g INTRAVENOUS ANDA 30 sections
Piperacillin, Tazobactam HUMAN PRESCRIPTION DRUG LABEL 2 25021-176 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 g INTRAVENOUS ANDA 30 sections